Aliases for GPR119 Gene
External Ids for GPR119 Gene
Previous GeneCards Identifiers for GPR119 Gene
This gene encodes a member of the rhodopsin subfamily of G-protein-coupled receptors that is expressed in the pancreas and gastrointestinal tract. The encoded protein is activated by lipid amides including lysophosphatidylcholine and oleoylethanolamide and may be involved in glucose homeostasis. This protein is a potential drug target in the treatment of type 2 diabetes.[provided by RefSeq, Jan 2010]
GeneCards Summary for GPR119 Gene
GPR119 (G Protein-Coupled Receptor 119) is a Protein Coding gene. Among its related pathways are Akt Signaling and GPCR Pathway. GO annotations related to this gene include G-protein coupled receptor activity and phosphatidylcholine binding. An important paralog of this gene is ADORA1.
UniProtKB/Swiss-Prot for GPR119 Gene
Receptor for the endogenous fatty-acid ethanolamide oleoylethanolamide (OEA) and lysophosphatidylcholine (LPC). Functions as a glucose-dependent insulinotropic receptor. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Seems to act through a G(s) mediated pathway.
GPR119 receptors, also referred to as SNORF25, RUP3, GPCR2 and OSGPR116, are Galphas-protein-coupled receptors with a degree of homology to cannabinoid receptors. They are predominantly expressed in the pancreas and gastrointestinal tract in humans and rodents. High expression levels are also seen in many areas of the rat brain, including the cerebellum, cerebral cortex, chorid plexus, dorsal root ganglion, hippocampus and hypothalamus. Ethanolamides are proposed to be the endogenous ligands for GPR119. Oleoylethanolamide (OEA) is the most potent endogenous GPR119 agonist identified to date, and the compound's effects on feeding are mediated through this receptor. GPR119 receptors are proposed to play a role in glucose homeostasis through modulation of insulin secretion. Activation of GPR119 receptors potentiates glucose-stimulated insulin secretion in a manner analogous to that of the incretin hormones glucagon-like peptide 1 (GLP-1) and gastric inhibitory poylpeptide (GIP). In addition, GPR119 agonists have been shown to directly stimulate GLP-1 and GIP secretion, which are both powerful antihyperglycemic agents. GPR119 receptors are attracting attention from antidiabetes and antiobesity researchers, as receptor modulation may provide favorable effects on glucose homeostasis, food intake, weight gain and possibly beta-islet cell preservation.